Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy

Abstract

The majority of lung cancer patients progressing from conventional therapies are refractory to PD‐L1/PD‐1 blockade monotherapy. Here, we show that baseline systemic CD4 immunity is a differential factor for clinical responses. Patients with functional systemic CD4 T cells included all objective responders and could be identified before the start of therapy by having a high proportion of memory CD4 T cells. In these patients, CD4 T cells possessed significant proliferative capacities, low co‐expression of PD‐1/LAG‐3 and were responsive to PD‐1 blockade ex vivo and in vivo . In contrast, patients with dysfunctional systemic CD4 immunity did not respond even though they had lung cancer‐specific T cells. Although proficient in cytokine production, CD4 T cells in these patients proliferated very poorly, strongly co‐upregulated PD‐1/LAG‐3, and were largely refractory to PD‐1 monoblockade. CD8 immunity only recovered in patients with functional CD4 immunity. T‐cell proliferative dysfunctionality could be reverted by PD‐1/LAG‐3 co‐blockade. Patients with functional CD4 immunity and PD‐L1 tumor positivity exhibited response rates of 70%, highlighting the contribution of CD4 immunity for efficacious PD‐L1/PD‐1 blockade therapy.

References 42

1. 1.

   Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, Rosenberg SA (2009 ) Tumor antigen‐specific CD8 T cells infiltrating the tumor express high levels of PD‐1 and are functionally impaired. Blood 114: 1537–1544

   Not in our library10.1182/blood-2008-12-195792

2. 2.

   Arakawa F, Kuroki M, Kuwahara M, Senba T, Ozaki H, Matsuoka Y, Misumi Y, Kanda H, Watanabe T (1996 ) Cloning and sequencing of the VH and V kappa genes of an anti‐CD3 monoclonal antibody, and construction of a mouse/human chimeric antibody. J Biochem 120: 657–662

   Not in our library10.1093/oxfordjournals.jbchem.a021462

3. 3.

   Azuma T, Yao S, Zhu G, Flies AS, Flies SJ, Chen L (2008 ) B7‐H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 111: 3635–3643

   Not in our library10.1182/blood-2007-11-123141

4. 4.

   Bigot F, Castanon E, Baldini C, Hollebecque A, Carmona A, Postel‐Vinay S, Angevin E, Armand JP, Ribrag V, Aspeslagh S et al (2017 ) Prospective validation of a prognostic score for patients in immunotherapy phase I trials: the Gustave Roussy Immune Score (GRIm‐Score). Eur J Cancer 84: 212–218

   Not in our library10.1016/j.ejca.2017.07.027

5. 5.

   Borghaei H, Paz‐Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E et al (2015 ) Nivolumab versus docetaxel in advanced nonsquamous non‐small‐cell lung cancer. N Engl J Med 373: 1627–1639

   Not in our library10.1056/nejmoa1507643

6. 6.

   Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K et al (2012 ) Safety and activity of anti‐PD‐L1 antibody in patients with advanced cancer. N Engl J Med 366: 2455–2465

   Not in our library10.1056/nejmoa1200694

7. 7.

   Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL (2004 ) SHP‐1 and SHP‐2 associate with immunoreceptor tyrosine‐based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 173: 945–954

   Not in our library10.4049/jimmunol.173.2.945

8. 8.

   Crawford A, Angelosanto JM, Kao C, Doering TA, Odorizzi PM, Barnett BE, Wherry EJ (2014 ) Molecular and transcriptional basis of CD4(+) T cell dysfunction during chronic infection. Immunity 40: 289–302

   Not in our library10.1016/j.immuni.2014.01.005

9. 9.

   Daud AI, Loo K, Pauli ML, Sanchez‐Rodriguez R, Sandoval PM, Taravati K, Tsai K, Nosrati A, Nardo L, Alvarado MD et al (2016 ) Tumor immune profiling predicts response to anti‐PD‐1 therapy in human melanoma. J Clin Invest 126: 3447–3452

   Not in our library10.1172/jci87324

10. 10.

    Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M et al (2009 ) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228–247

    Not in our library10.1016/j.ejca.2008.10.026

11. 11.

    Escors D, Lopes L, Lin R, Hiscott J, Akira S, Davis RJ, Collins MK (2008 ) Targeting dendritic cell signalling to regulate the response to immunisation. Blood 111: 3050–3061

    Not in our library10.1182/blood-2007-11-122408

12. 12.

    Faul F, Erdfelder E, Buchner A, Lang AG (2009 ) Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods 41: 1149–1160

    Not in our library10.3758/brm.41.4.1149

13. 13.

    Gato‐Canas M, Zuazo M, Arasanz H, Ibanez‐Vea M, Lorenzo L, Fernandez‐Hinojal G, Vera R, Smerdou C, Martisova E, Arozarena I et al (2017 ) PDL1 signals through conserved sequence motifs to overcome interferon‐mediated cytotoxicity. Cell Rep 20: 1818–1829

    Not in our library10.1016/j.celrep.2017.07.075

14. 14.

    Hashimoto M, Kamphorst AO, Im SJ, Kissick HT, Pillai RN, Ramalingam SS, Araki K, Ahmed R (2018 ) CD8 T cell exhaustion in chronic infection and cancer: opportunities for interventions. Annu Rev Med 69: 301–318

    Not in our library10.1146/annurev-med-012017-043208

15. 15.

    He Y, Yu H, Rozeboom L, Rivard CJ, Ellison K, Dziadziuszko R, Suda K, Ren S, Wu C, Hou L et al (2017 ) LAG‐3 protein expression in non‐small cell lung cancer and its relationship with PD‐1/PD‐L1 and tumor‐infiltrating lymphocytes. J Thorac Oncol 12: 814–823

    Not in our library10.1016/j.jtho.2017.01.019

16. 16.

    Herbst RS, Baas P, Kim DW, Felip E, Perez‐Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ et al (2016 ) Pembrolizumab versus docetaxel for previously treated, PD‐L1‐positive, advanced non‐small‐cell lung cancer (KEYNOTE‐010): a randomised controlled trial. Lancet 387: 1540–1550

    Not in our library10.1016/s0140-6736(15)01281-7

17. 17.

    Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz‐Ares L et al (2017 ) Nivolumab versus docetaxel in previously treated patients with advanced non‐small‐cell lung cancer: two‐year outcomes from two randomized, open‐label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol 35: 3924–3933

    Not in our library10.1200/jco.2017.74.3062

18. 18.

    Huang RY, Francois A, McGray AR, Miliotto A, Odunsi K (2017 ) Compensatory upregulation of PD‐1, LAG‐3, and CTLA‐4 limits the efficacy of single‐agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology 6: e1249561

    Not in our library10.1080/2162402x.2016.1249561

19. 19.

    Hui E, Cheung J, Zhu J, Su X, Taylor MJ, Wallweber HA, Sasmal DK, Huang J, Kim JM, Mellman I et al (2017 ) T cell costimulatory receptor CD28 is a primary target for PD‐1‐mediated inhibition. Science 355: 1428–1433

    Not in our library10.1126/science.aaf1292

20. 20.

    Johnson DB, Nixon MJ, Wang Y, Wang DY, Castellanos E, Estrada MV, Ericsson‐Gonzalez PI, Cote CH, Salgado R, Sanchez V et al (2018 ) Tumor‐specific MHC‐II expression drives a unique pattern of resistance to immunotherapy via LAG‐3/FCRL6 engagement. JCI Insight 3: 120360

    Not in our library10.1172/jci.insight.120360

21. 21.

    Juneja VR, McGuire KA, Manguso RT, LaFleur MW, Collins N, Haining WN, Freeman GJ, Sharpe AH (2017 ) PD‐L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med 214: 895–904

    Not in our library10.1084/jem.20160801

22. 22.

    Kamphorst AO, Pillai RN, Yang S, Nasti TH, Akondy RS, Wieland A, Sica GL, Yu K, Koenig L, Patel NT et al (2017a ) Proliferation of PD‐1+ CD8 T cells in peripheral blood after PD‐1‐targeted therapy in lung cancer patients. Proc Natl Acad Sci USA 114: 4993–4998

    Not in our library10.1073/pnas.1705327114

23. 23.

    Kamphorst AO, Wieland A, Nasti T, Yang S, Zhang R, Barber DL, Konieczny BT, Daugherty CZ, Koenig L, Yu K et al (2017b ) Rescue of exhausted CD8 T cells by PD‐1‐targeted therapies is CD28‐dependent. Science 355: 1423–1427

    Not in our library10.1126/science.aaf0683

24. 24.

    Karwacz K, Bricogne C, Macdonald D, Arce F, Bennett CL, Collins M, Escors D (2011 ) PD‐L1 co‐stimulation contributes to ligand‐induced T cell receptor down‐modulation on CD8(+) T cells. EMBO Mol Med 3: 581–592

    Not in our library10.1002/emmm.201100165

25. 25.

    Knocke S, Fleischmann‐Mundt B, Saborowski M, Manns MP, Kuhnel F, Wirth TC, Woller N (2016 ) Tailored tumor immunogenicity reveals regulation of CD4 and CD8 T cell responses against cancer. Cell Rep 17: 2234–2246

    Not in our library10.1016/j.celrep.2016.10.086

26. 26.

    Kreiter S, Vormehr M, van de Roemer N, Diken M, Lower M, Diekmann J, Boegel S, Schrors B, Vascotto F, Castle JC et al (2015 ) Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520: 692–696

    Not in our library10.1038/nature14426

27. 27.

    Krieg C, Nowicka M, Guglietta S, Schindler S, Hartmann FJ, Weber LM, Dummer R, Robinson MD, Levesque MP, Becher B (2018 ) High‐dimensional single‐cell analysis predicts response to anti‐PD‐1 immunotherapy. Nat Med 24: 144–153

    Not in our library10.1038/nm.4466

28. 28.

    Lanna A, Henson SM, Escors D, Akbar AN (2014 ) The kinase p38 activated by the metabolic regulator AMPK and scaffold TAB 1 drives the senescence of human T cells. Nat Immunol 15: 965–972

    Not in our library10.1038/ni.2981

29. 29.

    Lanna A, Gomes DC, Muller‐Durovic B, McDonnell T, Escors D, Gilroy DW, Lee JH, Karin M, Akbar AN (2017 ) A sestrin‐dependent Erk‐Jnk‐p38 MAPK activation complex inhibits immunity during aging. Nat Immunol 18: 354–363

    Not in our library10.1038/ni.3665

30. 30.

    Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D et al (2015 ) PD‐1 blockade in tumors with mismatch‐repair deficiency. N Engl J Med 372: 2509–2520

    Not in our library10.1056/nejmoa1500596

31. 31.

    Liechtenstein T, Perez‐Janices N, Blanco‐Luquin I, Schwarze J, Dufait I, Lanna A, De Ridder M, Guerrero‐Setas D, Breckpot K, Escors D (2014 ) Anti‐melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD‐L1 characterized using ex vivo myeloid‐derived suppressor cells as a readout of therapeutic efficacy. Oncoimmunology 3: e29178

    Not in our library10.4161/21624011.2014.945378

32. 32.

    Madoz‐Gurpide J, Kuick R, Wang H, Misek DE, Hanash SM (2008 ) Integral protein microarrays for the identification of lung cancer antigens in sera that induce a humoral immune response. Mol Cell Proteomics 7: 268–281

    Not in our library10.1074/mcp.m700366-mcp200

33. 33.

    Markowitz GJ, Havel LS, Crowley MJ, Ban Y, Lee SB, Thalappillil JS, Narula N, Bhinder B, Elemento O, Wong ST et al (2018 ) Immune reprogramming via PD‐1 inhibition enhances early‐stage lung cancer survival. JCI Insight 3: 96836

    Not in our library10.1172/jci.insight.96836

34. 34.

    Mishra AK, Kadoishi T, Wang X, Driver E, Chen Z, Wang XJ, Wang JH (2016 ) Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co‐expressing PD‐1 and LAG‐3 inhibitory receptors. Oncotarget 7: 81341–81356

    Not in our library10.18632/oncotarget.13228

35. 35.

    Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC et al (2017 ) Atezolizumab versus docetaxel in patients with previously treated non‐small‐cell lung cancer (OAK): a phase 3, open‐label, multicentre randomised controlled trial. Lancet 389: 255–265

    Not in our library10.1016/s0140-6736(16)32517-x

36. 36.

    Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Lower M, Bukur V, Tadmor AD, Luxemburger U, Schrors B et al (2017 ) Personalized RNA mutanome vaccines mobilize poly‐specific therapeutic immunity against cancer. Nature 547: 222–226

    Not in our library10.1038/nature23003

37. 37.

    Scapin G, Yang X, Prosise WW, McCoy M, Reichert P, Johnston JM, Kashi RS, Strickland C (2015 ) Structure of full‐length human anti‐PD1 therapeutic IgG4 antibody pembrolizumab. Nat Struct Mol Biol 22: 953–958

    Not in our library10.1038/nsmb.3129

38. 38.

    Spitzer MH, Carmi Y, Reticker‐Flynn NE, Kwek SS, Madhireddy D, Martins MM, Gherardini PF, Prestwood TR, Chabon J, Bendall SC et al (2017 ) Systemic immunity is required for effective cancer immunotherapy. Cell 168: 487–502 e415

    Not in our library10.1016/j.cell.2016.12.022

39. 39.

    Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB et al (2012 ) Safety, activity, and immune correlates of anti‐PD‐1 antibody in cancer. N Engl J Med 366: 2443–2454

    Not in our library10.1056/nejmoa1200690

40. 40.

    Topalian SL, Taube JM, Anders RA, Pardoll DM (2016 ) Mechanism‐driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 16: 275–287

    Not in our library10.1038/nrc.2016.36

41. 41.

    Williams JB, Horton BL, Zheng Y, Duan Y, Powell JD, Gajewski TF (2017 ) The EGR2 targets LAG‐3 and 4‐1BB describe and regulate dysfunctional antigen‐specific CD8+ T cells in the tumor microenvironment. J Exp Med 214: 381–400

    Not in our library10.1084/jem.20160485

42. 42.

    Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G et al (2009 ) Guidelines for the evaluation of immune therapy activity in solid tumors: immune‐related response criteria. Clin Cancer Res 15: 7412–7420

    Not in our library10.1158/1078-0432.ccr-09-1624

Cited by papers we hold 3

• Understanding LAG-3 Signaling · 2021
  No notice
• Medical Treatment of Lung Cancer: Can Immune Cells Predict the Response? A Systematic Review · 2020
  Not checked
• Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.